Latest news with #Semaglutide
Yahoo
a day ago
- Health
- Yahoo
Mama June Praises The Benefits Of Weight Loss Shots After Quitting It
Mama June is in her healthy era! The reality star is choosing to live a healthy life, and the process has been rewarding, as she has now discontinued her weight loss medications. Mama June's struggle with weight management has been a central point in her life for years. She previously went under the knife for weight loss surgery in 2016. The TV star recently shared exciting news about her health journey, revealing she has stopped using weight loss medication. Mama June confirmed that she has not relied on weight loss shots since December and has successfully maintained her weight through lifestyle changes. She highlighted the benefits of weight loss shots, particularly for individuals managing medical conditions. "I tell you all the time, if you choose to go on the weight loss shot, it has so many benefits. Not just for weight loss, but for, like, people who have like PCOS, women's issues, people who have inflammation, people who have other issues going on," she said. The reality star began her weight loss journey with injections in April 2024, eight years after undergoing weight loss surgery in 2016, which helped her reach a weight of 195 pounds. However, she struggled to maintain her weight as she faced challenges during her eldest daughter Anna Cardwell's cancer battle. Mama June was even more overwhelmed when her efforts to salvage Anna's life did not yield, and she unfortunately passed at the age of 29 in December 2023. In June 2024, June opened up about taking medications for her weight loss. In her words: "I've been on weight loss medication. I was first on Semaglutide, which is like Ozempic. And now I'm on Triglycerides for the last three weeks." She also claimed the medications were super helpful at the time, with zero side effects to threaten her health. Today, In Touch confirmed that she appears to be focusing on her health sustainably, celebrating her progress while promoting the new season of "Mama June: Family Crisis." In her revelation last year, she added that she also kept the weight off by exercising "three or four times a week." She reflected on her past experiences with gastric procedures, expressing her initial aversion to the potential side effects like nausea and vomiting. However, she noted that since starting her new medication, she has experienced no adverse effects and has avoided sweets and sodas. June mentioned that while diabetes medications are often associated with lowering blood sugar, she has had no issues in that area since beginning treatment. She spotted the difference in weight loss rates between her previous surgery and the medication. According to her: "I've just been really good and consistent. The only difference [for] this medicine and the gastric sleeve is I lost 160 pounds in four weeks [with the surgery] and with this I lose four pounds a week." The reality star has documented her weight loss on social media, sharing that as of September 2024, she had lost a total of 60 pounds. Since Anna's passing, a whole lot has changed for Mama June and her family. Her last daughter, Alana, now 19, has relocated to Colorado to pursue a degree in nursing. Alana became popular on TV following her appearance on TLC's "Toddlers & Tiaras." She quickly became a reality TV sensation with her confident catchphrase, "Honey Boo Boo Child!" Along with her entertaining family, she starred in a series of shows and specials that instantly brought her fame. Reflecting on her rise to stardom, Alana expressed her bewilderment over how she came up with her iconic phrase, stating, "To this day, I still cannot tell you what I thought when I was saying 'Honey Boo Boo Child.'" Now that she has moved to Georgia, which she had always known as home, Alana admits, "Absolutely, no. I do not miss Georgia. I don't miss a thing about Georgia," though she acknowledges missing the people she left behind. With a sense of humor about her past as a reality star, she noted that she might still be known as 'Honey Boo Boo' even at 60, joking about being approached for photos in a nursing home. Anna's battle with cancer has also intensified Alana's desire to help others. She was deeply affected by the care Anna received and the positive impact of her nurses, which inspired Alana to pursue a career in nursing. As shared by TODAY, she expressed her aspiration to be a supportive nurse, reflecting her commitment to helping others in times of need. Last year, The Blast shared that Mama June opened up about the profound emptiness left by her daughter Anna Cardwell's passing. She shared the challenging reality her family has faced since losing Anna, detailing the impact on her granddaughters, 12-year-old Kaitlyn and 8-year-old Kylee. The loss has been especially difficult for the girls, with Mama June noting the significant struggles they have had to endure. In addition to dealing with the grief, Mama June has navigated a complicated custody situation. Following Anna's death, she fought and won a custody battle for Kaitlyn against her former son-in-law, Michael Cardwell. This battle was worsened by Michael's move to Alabama, which disrupted their family arrangement. Mama June decided to stay in Georgia despite her plans to relocate to prevent Kylee from moving away. Despite the daunting situation, Mama June shared her commitment to keeping Anna's husband, Eldridge Toney, involved in the lives of her granddaughters, honoring Anna's wishes in the process. Things got heated during the custody battle with Michael. While Anna's former husband claimed Anna and Mama June were not on good terms before her death, the reality star set the record straight. According to Mama June, Michael was the abusive one during his marriage to her late daughter. She claimed Michael constantly abused Anna and Kaitlyn. The court eventually ruled that Mama June would retain Kaitlyn's legal and physical custody. The court also placed restrictions on Michael, prohibiting him from contacting Mama June or Kaitlyn unless they both agreed to a visitation arrangement. Kaitlyn, who has been residing with her grandmother since Anna's battle with cancer, had previously expressed her strong desire to stay with Mama June during testimony in court. Big ups to Mama June for doing the best for her wellness despite what life is throwing at her.
News18
2 days ago
- Business
- News18
Stocks To Watch: IndiGo, Tata Motors, BPCL, Vodafone Idea, BPCL, Nykaa, And Others
Last Updated: Stocks to watch: Shares of firms like IndiGo, Tata Motors, BPCL, Vodafone Idea, BPCL, Nykaa, and others will be in focus on Monday's trade Stocks to Watch on June 2: Indian equity markets began the June expiry on a cautious note, ending marginally lower amid continued consolidation. In today's trade, shares of Apollo Hospitals, IndiGo, Tata Motors, BPCL, Vodafone Idea, and others will be in focus due to significant news and quarterly earnings updates. IndiGo IndiGo CEO Pieter Elbers said the airline welcomed the three-month extension (granted till August 2025) for its 'damp-leased' aircraft from Turkish Airlines by the DGCA. This move will support ongoing operations and customer commitments. Tata Motors Tata Motors reported an 8.6% YoY decline in total sales to 70,187 units in May 2025, compared to 76,766 units in the same period last year. Domestic sales fell 10% to 67,429 units. TVS Motor TVS Motor's total sales rose 17% YoY to 4.31 lakh units in May, up from 3.69 lakh units a year earlier. Two-wheeler sales jumped 16% to 4.16 lakh units versus 3.59 lakh units last year. BPCL BPCL's board approved an investment in a joint venture with Tikitar and Shell India, aimed at manufacturing and marketing bitumen products. Dr Reddy's Dr Reddy's said the matter of Novo Nordisk's Semaglutide patents in India remains sub-judice. Vodafone Idea reported a narrowed loss of Rs 7,166 crore for the March quarter. The telco's board has also approved a fundraising plan of up to Rs 20,000 crore, pending shareholder and regulatory approvals. EaseMyTrip EaseMyTrip posted a sharp 59% QoQ decline in net profit for Q4FY25 to Rs 139 crore, down from Rs 150 crore in Q3 FY25 — a decrease of 7.33%. Senco Gold Senco Gold Ltd reported a 94% YoY surge in consolidated net profit to Rs 62.44 crore in Q4FY25, driven by strong sales. Revenue for the quarter stood at Rs 1,377.71 crore, up from Rs 1,137.28 crore last year. Som Distilleries Som Distilleries & Breweries Ltd saw an 18.8% rise in consolidated net profit to Rs 23.73 crore in Q4FY25, aided by IMFL volume growth and higher realisations. Apollo Hospitals Apollo Hospitals Enterprise reported a robust 54% YoY jump in consolidated profit after tax to Rs 390 crore for the March 2025 quarter, supported by strong sales. Nykaa Nykaa's parent, FSN Ecommerce Ventures, posted a threefold YoY increase in consolidated net profit to Rs 20.28 crore in Q4. Revenue rose 23.6% to Rs 2,061.76 crore, up from Rs 1,667.98 crore a year earlier. Inox Wind Inox Wind Ltd posted a fivefold jump in consolidated net profit to Rs 190.34 crore in Q4FY25, as revenues surged. Income more than doubled to Rs 1,310.65 crore from Rs 569.04 crore in the previous year. Disclaimer: First Published: June 02, 2025, 07:51 IST News business » markets Stocks To Watch: IndiGo, Tata Motors, BPCL, Vodafone Idea, BPCL, Nykaa, And Others
Economic Times
2 days ago
- Business
- Economic Times
Stocks in news: Apollo Hospitals, IndiGo, Tata Motors, BPCL, Vodafone Idea
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Markets began the June expiry on a muted note and ended marginally lower, continuing the ongoing consolidation phase. In today's trade, shares of Apollo Hospitals Vodafone Idea among others will be in focus due to various news developments and fourth quarter CEO Pieter Elbers said that the three-month extension, granted till August 2025, for the 'damp-leased' aircraft from Turkish Airlines by DGCA will help the airline manage ongoing operations and customer Motors reported a decline in overall sales, with total sales down 8.6% year-on-year at 70,187 units in May 2025, compared to 76,766 units last year, while domestic sales dropped 10% to 67,429 sales rose 17% year-on-year to 4.31 lakh units in May, compared to 3.69 lakh units last year, with two-wheeler sales up 16% at 4.16 lakh units versus 3.59 lakh units in the same board has approved an investment in a joint venture with Tikitar and Shell India, aimed at manufacturing and marketing bitumen products. Alembic Pharmaceuticals has received a Form 483 from the US FDA with four observations for its API-I and API-II manufacturing units at India has filed the draft red herring prospectus (DRHP) for its subsidiary Bharat Coking Coal Ltd (BCCL) with Sebi. The proposed IPO will be an offer for sale (OFS) of up to 46.57 crore shares by Coal Reddy's said on Novo Nordisk's Semaglutide patents in India that the matter is currently Hospitals Enterprise reported fourth-quarter profit above market estimates on Friday, driven by higher demand for its healthcare products retailer Nykaa posted a fourth-quarter profit that nearly tripled year on year as premium brands continued to attract urban telco Vodafone Idea reported narrowing of losses for the March quarter to Rs 7,166 crore and its board greenlit fundraising of up to Rs 20,000 crore subject to shareholders' approval and statutory nods.
Time of India
2 days ago
- Business
- Time of India
Stocks in news: Apollo Hospitals, IndiGo, Tata Motors, BPCL, Vodafone Idea
Markets began the June expiry on a muted note and ended marginally lower, continuing the ongoing consolidation phase. In today's trade, shares of Apollo Hospitals , IndiGo , Tata Motors , BPCL , Vodafone Idea among others will be in focus due to various news developments and fourth quarter results. IndiGo IndiGo CEO Pieter Elbers said that the three-month extension, granted till August 2025, for the 'damp-leased' aircraft from Turkish Airlines by DGCA will help the airline manage ongoing operations and customer commitments. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Access all TV channels anywhere, anytime Techno Mag Learn More Undo Tata Motors Tata Motors reported a decline in overall sales, with total sales down 8.6% year-on-year at 70,187 units in May 2025, compared to 76,766 units last year, while domestic sales dropped 10% to 67,429 units. TVS Motor Total sales rose 17% year-on-year to 4.31 lakh units in May, compared to 3.69 lakh units last year, with two-wheeler sales up 16% at 4.16 lakh units versus 3.59 lakh units in the same period. Live Events BPCL BPCL board has approved an investment in a joint venture with Tikitar and Shell India, aimed at manufacturing and marketing bitumen products. Alembic Pharma Alembic Pharmaceuticals has received a Form 483 from the US FDA with four observations for its API-I and API-II manufacturing units at Panelav. Coal India Coal India has filed the draft red herring prospectus (DRHP) for its subsidiary Bharat Coking Coal Ltd (BCCL) with Sebi. The proposed IPO will be an offer for sale (OFS) of up to 46.57 crore shares by Coal India. Dr Reddy's Dr Reddy's said on Novo Nordisk's Semaglutide patents in India that the matter is currently sub-judice. Apollo Hospitals Apollo Hospitals Enterprise reported fourth-quarter profit above market estimates on Friday, driven by higher demand for its healthcare services. Nykaa Beauty products retailer Nykaa posted a fourth-quarter profit that nearly tripled year on year as premium brands continued to attract urban consumers. Vodafone Idea Debt-ridden telco Vodafone Idea reported narrowing of losses for the March quarter to Rs 7,166 crore and its board greenlit fundraising of up to Rs 20,000 crore subject to shareholders' approval and statutory nods.
Business Upturn
5 days ago
- Business
- Business Upturn
Nomura maintains ‘Buy' on Alkem Labs; expects Semaglutide launch to drive future growth
By Markets Desk Published on May 30, 2025, 07:46 IST Nomura has reiterated its Buy rating on Alkem Labs with a target price of ₹5,430, viewing the Q4FY25 earnings as largely in line on sales, though EBITDA and PAT came in 2% and 6% below estimates, respectively. The company's FY26 guidance is described as a mixed bag. One key concern is an expected rise in effective tax rate (ETR) to 35–37% in FY27E, which is significantly higher than Nomura's current 20% assumption. While this will negatively impact reported earnings, cash flows remain unaffected, as cash tax will stay around 17–18%. On the operational front, domestic formulations are expected to grow ~100bps ahead of the market in FY26. The company also expects to be in the first wave of Semaglutide launches in India by March 2026, which could be a major growth driver. Disclaimer: The views and target prices mentioned in this article are as stated by Nomura. They do not represent the opinions or recommendations of this publication. Readers are advised to consult their financial advisors before making any investment decisions. Markets Desk at
